RANI THERAPEUTICS HOLDINGS, INC.

(RANI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Rani Therapeutics Holdings, Inc.(NasdaqGM:RANI) added to NASDAQ Biotechnology Index

12/20/2021 | 12:00am EDT

Rani Therapeutics Holdings, Inc. has been added to NASDAQ Biotechnology Index.


© S&P Capital IQ 2021
All news about RANI THERAPEUTICS HOLDINGS, INC.
05/12Rani Therapeutics Posts Q1 Loss, Operating Expenses Rise
MT
05/11RANI THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Con..
AQ
05/11Rani Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended M..
CI
05/11Rani Therapeutics Reports First Quarter 2022 Financial Results; Provides Corporate Upda..
AQ
05/03Rani Therapeutics to Present at Upcoming Investor Conferences
AQ
05/03Rani Therapeutics' RaniPill™ Capsule Named Winner in the Health Category of Fast ..
AQ
04/14TRANSCRIPT : Rani Therapeutics Holdings, Inc. Presents at Needham 21st Annual Healthcare C..
CI
04/07Rani Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
AQ
03/31RANI THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Con..
AQ
03/29RANI THERAPEUTICS : Reports Fourth Quarter and Full Year 2021 Financial Results; Provides ..
PU
More news
Analyst Recommendations on RANI THERAPEUTICS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 0,25 M - -
Net income 2022 -81,1 M - -
Net Debt 2022 - - -
P/E ratio 2022 -7,59x
Yield 2022 -
Capitalization 282 M 282 M -
Capi. / Sales 2022 1 126x
Capi. / Sales 2023 -
Nbr of Employees 114
Free-Float 12,4%
Chart RANI THERAPEUTICS HOLDINGS, INC.
Duration : Period :
Rani Therapeutics Holdings, Inc. Technical Analysis Chart | RANI | US7530181004 | MarketScreener
Technical analysis trends RANI THERAPEUTICS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 11,50 $
Average target price 26,60 $
Spread / Average Target 131%
EPS Revisions
Managers and Directors
Talat Imran Chief Executive Officer & Director
Svai S. Sanford Chief Financial Officer
Mir A. Imran Executive Chairman
Mir Hashim Chief Scientific Officer
Arvinder Dhalla Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
RANI THERAPEUTICS HOLDINGS, INC.-29.66%267
MODERNA, INC.-43.98%54 199
LONZA GROUP AG-28.13%40 453
IQVIA HOLDINGS INC.-26.74%39 077
SEAGEN INC.-5.21%26 238
ICON PUBLIC LIMITED COMPANY-32.47%17 114